# Coding Pitfalls Case Scenarios

## Breast Case Scenario

The summary below is an aide meant to help follow along with the presentation. Participants do **not** need to complete the scenario prior to the session.

History:

A 42 year old female presents with a palpable left breast mass. The axilla area was negative for enlarged lymph nodes.

Imaging:

* Mammogram showed a left breast mass at 10 o’clock measuring 3cm.
* Ultrasound of the left breast: 2 cm mass @10:00 and a left axillary lymph node measuring 1.1 cm

Pathology:

* Biopsy of the breast @10:00: positive for carcinoma NST with tubular carcinoma, NG grade 2, areas of high grade DCIS
	+ ER 95% (positive)
	+ PR 81-90% (positive)
	+ Ki-67 44% (H)
	+ HER2 by Immunohistochemistry 2+
	+ HER2 by in situ hybridization Positive (amplified)
	+ HER2: CEP17 ratio 1.34
	+ Average HER2 signals/nucleus 4.75
	+ Average CEP17 signals/nucleus 3.55
* Biopsy of left axillary lymph node: Negative for malignancy
* Mastectomy:
	+ No residual carcinoma (complete PR)
	+ 0/4 SLN, IHC negative

Treatment:

* Neoadjuvant chemotherapy: 6 cycles of TCHP
* Surgery: Bilateral nipple sparing mastectomy, sentinel lymph node biopsy, tissue expander reconstruction.

Discharge Summary:

* Patient had a complete pathologic response to neoadjuvant treatment.

|  |
| --- |
| Scenario 1-Breast |
| Primary Site | C50.2 | Clinical Grade | 2 | Tumor Size Clinical | 030 |
| Histology | 8523 | Pathological Grade | 9 | Tumor Size Pathological | 000 |
| Behavior | 3 | Post Therapy Grade | 9 | Tumor Size Summary | 030 |
| MP Rule | M3 |  |
| H Rule | H4 and then H15 |
|  |
| Stage Data items |
| Clinical T | cT2 | Pathological T |  | Post-therapy T | ypT0 |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N | cN0 | Pathological N |  | Post-therapy N | ypN0 |
| cN Suffix |  (f) | pN Suffix |  | pN Suffix | (sn) |
| Clinical M | cM0 | Pathological M |  | Post-therapy M | cM0 |
| Clinical Stage  | 1B | Pathological Stage |  | Post-therapy Stage | 88 |
|  |
| Summary Stage 2018  | 1-Localized |
| EOD Primary Tumor | 100 |
| EOD Regional Nodes | 070 |
| EOD Mets  | 00 |
| Regional Nodes Positive | 00 |
| Regional Nodes Examined | 04 |
| Sentinel Nodes Positive | 00 |
| Sentinel Nodes Examined | 04 |
|  |
| SSDI’s |
| *Positive AxLN Level I-II* | 00 |
| ER Summary  |  1 |
| ER Percent Positive | 095 |
| ER Allred Score | X9 |
| PR Summary | 1 |
| PR Percent Positive | R90 |
| PR Allred Score | X9 |
| HER2 IHC Summary | 2 |
| HER2 ISH Summary | 3 |
| HER2 Overall Summary | 1 |
| HER2 ISH DP Ratio | 1.3 |
| HER2 ISH DP Copy No | 4.7 |
| HER2 ISH SP Copy No | XX.9 |
| Ki-67 (MIB-1) | 44.0 |
| Oncotype DX Recur Score | XX9 |
| Oncotype Dx Risk Level Invasive | 9 |
| Oncotype DX Recur Score - DCIS | XX6 |
| Oncotype Dx Risk Level – DCIS | 6 |
| Multigene Signature Method | 9 |
| Multigene Signature Result | X9 |
| Response Neoadjuvant Therapy  | 1 |
|  |
| Diagnostic Staging Procedure | 02 |
|  |
| Surgery |
| Surgical Procedure of Primary Site | 30 |
| Scope of Regional Lymph Node Surgery | 2 |
| Surgical Procedure/ Other Site | 0 |
| Systemic Therapy |
| Chemotherapy | 03 |
| Hormone Therapy | 88 |
| Immunotherapy | 01 |
| Hematologic Transplant | 00 |
| Systemic/ Surgery Sequence | 7 |
|  |  |
| Radiation |
|  | Phase 1 | Phase 2 | Phase 3 |
| Rad Primary Treatment Volume | 00 |  |  |
| Rad Treatment Modality | 00 |  |  |
| Radiation to Draining Lymph Nodes |  |  |  |
| Ext Beam Rad Planning Technique |  |  |  |
| Dose per Fraction |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose |  |  |  |
| # of Phases of Rad Tx to this Volume | 00 |
| Rad Treatment Discontinued Early | 00 |
| Total Dose | 000000 |
| Reason no Radiation  | 1 |

## Colon Case Scenario

**History**

Patient had a transverse colectomy for adenocarcinoma of the transverse colon on 4/25/16. The patient presents today for a follow-up barium enema and colonoscopy.

* Labs: 7/25/18 CEA 17 ng/ml (normal < 3 ng/ml)
* Imaging: 7/25/18
	+ BE: 2.5 cm polypoid lesion at the anastomotic site shows the typical features of colonic CA
	+ CT chest/abd/pel: no evidence of metastasis
* Scopes 7/25/18 Colonoscopy: submucosal tumor located at suture line; biopsies taken
* Treatment 8/24/18 Right hemicolectomy

**Pathology**

7/25/18 Biopsy at anastomosis: Moderately differentiated adenocarcinoma.

8/24/18 Right colon with anastomosis:

* 2.9 cm well differentiated adenocarcinoma with mucinous differentiation at anastomotic site
* Tumor invades muscularis propria;
* LVI: None
* PNI: None
* Proximal, distal, and radial margins free
* 16 lymph nodes negative for metastasis
* A single peritumoral deposit
* MSI low
* KRAS mutated

**Discharge summary**:

Clinicopathological examination showed the lesion was a recurrence of the previous trans-colon cancer, because it was located exactly on the anastomosis and it first showed a feature of submucosal tumor. Plan: FOLFOX

|  |
| --- |
| Scenario 2-Colon |
| Primary Site | **C18.9** | Clinical Grade | 2 | Tumor Size Clinical | 025 |
| Histology | 8140 | Pathological Grade | 2 | Tumor Size Pathological | 029 |
| Behavior | 3 | Post Therapy Grade |  | Tumor Size Summary | 029 |
| MP Rule | M7 |  |
| H Rule | H7 |
|  |
| Stage Data items |
| Clinical T | cTX | Pathological T | pT2 | Post-therapy T |  |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N | cN0 | Pathological N | pN1c | Post-therapy N |  |
| cN Suffix |  | pN Suffix |  | pN Suffix |  |
| Clinical M | cM0 | Pathological M | cM0 | Post-therapy M |  |
| Clinical Stage  | 99 | Pathological Stage | 3A | Post-therapy Stage |  |
|  |
| Summary Stage 2018  | 3-Regional to Lymph Nodes |
| EOD Primary Tumor | 200 |
| EOD Regional Nodes | 200 |
| EOD Mets  | 00 |
| Regional Nodes Positive | 00 |
| Regional Nodes Examined | 16 |
| Sentinel Nodes Positive | 98 |
| Sentinel Nodes Examined | 98 |
|  |
| SSDI’s |
| CEA PreTX Lab Value | 17.0 |
| CEA PreTX Interpretation | 1 |
| Tumor Deposits | 01 |
| Circumferential Resection Margin | XX.1 |
| KRAS | 4 |
| Microsatellite Instability (MSI) | 1 |
|  |
| Diagnostic Staging Procedure | 02 |
|  |
| Surgery |
| Surgical Procedure of Primary Site | 40 |
| Scope of Regional Lymph Node Surgery | 4 |
| Surgical Procedure/ Other Site | 0 |
| Systemic Therapy |
| Chemotherapy | 88 |
| Hormone Therapy | 00 |
| Immunotherapy | 00 |
| Hematologic Transplant | 00 |
| Systemic/ Surgery Sequence | 0 |
|  |  |
| Radiation |
|  | Phase 1 | Phase 2 | Phase 3 |
| Rad Primary Treatment Volume | 00 |  |  |
| Rad Treatment Modality |  |  |  |
| Radiation to Draining Lymph Nodes |  |  |  |
| Ext Beam Rad Planning Technique |  |  |  |
| Dose per Fraction |  |  |  |
| Number of Fractions |  |  |  |
| Total Dose |  |  |  |
| # of Phases of Rad Tx to this Volume | 00 |
| Rad Treatment Discontinued Early | 00 |
| Total Dose | 000000 |
| Reason no Radiation  | 1 |